
|Articles|July 1, 2002
Anti-VEGF therapy holds promise for CNV in AMD
Author(s)Laszlo Dosa
Fort Lauderdale, FL-Anti-vascular endothelial growth factor (anti-VEGF) therapy is a promising treatment of neovascularization brought on by various ocular diseases, including age-related macular degeneration (AMD), according to Lawrence J. Singerman, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Rayner’s RayOne EMV Toric intraocular lens
2
Ophthalmic innovation by the decades: The 2000s
3
EyePoint Pharmaceuticals details phase 3 program evaluating vorolanib intravitreal insert (DURAVYU) for DME
4
Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA
5